Latest news with #Atrovent
&w=3840&q=100)
Business Standard
16 hours ago
- Business
- Business Standard
Lupin launches nasal spray in US, part of 200-drug pipeline by FY30
Indian pharmaceutical major Lupin on Thursday announced the launch of a new nasal spray — Ipratropium Bromide Nasal Solution — in the United States market. The product is available in two strengths: 0.03 per cent and 0.06 per cent. The company stated that the spray is used to treat runny nose (rhinorrhoea) caused by allergies, the common cold or other non-allergic conditions. It is suitable for both adults and children, depending on the prescribed strength. The product is the generic version of a nasal spray called Atrovent, which is already available in the US market. The spray is considered bioequivalent, meaning it acts in the same way in the body as the reference drug. Lupin has a strong presence in the US and European pharmaceutical markets. As reported by Business Standard in May, the company is targeting a greater share of revenue from its complex generics portfolio in the US and Europe. With a pipeline of over 200 products over the next five years, Lupin expects the revenue share from complex generics to reach 62 per cent by FY30. The contribution from such products is projected at 21 per cent by FY26. Complex generics include high-value products such as inhalers, injectables, transdermal patches and ophthalmic solutions, which typically contain more sophisticated active ingredients and delivery mechanisms. Generic drugs are copies of branded medicines that have gone off-patent. Complex generics differ from simple generics in terms of formulation, technology and margin potential. On Friday, Lupin's shares closed at ₹1,978 on the Bombay Stock Exchange, up ₹22.40 or 1.15 per cent.
Time of India
18 hours ago
- Business
- Time of India
Lupin launches Ipratropium Bromide nasal spray in US
Pharma major Lupin Ltd on Friday said it has launched Ipratropium Bromide nasal spray , used in treatment of runny nose, in the US market. The Ipratropium Bromide nasal solution (nasal spray) launched in the US is of strengths 0.03 per cent and 0.06 per cent, Lupin Ltd said in a regulatory filing. Ipratropium Bromide nasal spray 0.03 per cent and 0.06 per cent are bioequivalent to Atrovent nasal spray in the same strengths of Boehringer Ingelheim Pharmaceuticals , Inc, it added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo Lupin said Ipratropium Bromide nasal spray 0.03 per cent is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. Ipratropium Bromide nasal spray 0.06 per cent is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older, it added. Live Events Citing IQVIA MAT May 2025 data, the company said Ipratropium Bromide nasal solution (Atrovent) had estimated annual sales of USD 63 million in the US. PTI
